KYORIN Pharmaceutical Co., Ltd.
Promotion activities for the allergy conjunctivitis treatment ‘Allegion® Eyelid Cream 0.5%’
Joint promotional activities for Allegion® Eyelid Cream 0.5% in the Japanese market with Santen. The target area is medical institutions other than ophthalmology. If disclosure reasons arise affecting the consolidated earnings forecast for the fiscal year ending March 2027, notification will be made promptly. The product is world’s first once-daily application formulation.
Key Figures
- Promotion start date for Allegion® Eyelid Cream 0.5%: 2026-08-17
- Joint promotional agreement signing date: 2026-07-13
- Disclosure policy for impact on the FY2027 earnings forecast: Will promptly notify upon disclosure trigger
AI要約
Overview of the news
Kyorin Pharmaceutical will commence promotional activities for Allegion® Eyelid Cream 0.5% from August 17, 2026. A joint promotional agreement was signed with Santen on July 13, 2026, with Santen handling manufacturing, sales, and ophthalmology-area promotions, while Kyorin Pharmaceutical will promote to medical institutions outside the ophthalmology field. The aim is to expand treatment options for allergic conjunctivitis and improve patient QoL.
Financial impact and future outlook
As for the impact on the consolidated earnings forecast for the fiscal year ending March 2027, the company will promptly notify if there are any disclosure-related reasons. At present, no specific financial figures are available.
Kyorin Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
